Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;14(2):310-313.
doi: 10.21037/tlcr-24-961. Epub 2025 Feb 21.

Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most

Eric Santoni-Rugiu  1   2 , Jens Benn Sørensen  2   3 , Edyta Maria Urbanska  3
Affiliations
Editorial

Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most

Eric Santoni-Rugiu et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Adjuvant alectinib; anaplastic lymphoma kinase-rearranged NSCLC (ALK-rearranged NSCLC); resected early-stage non-small cell lung cancer (resected early-stage NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-961/coif). E.S.R. has received research grants from Sanofi and Takeda; honoraria for lectures from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, and Takeda; and payment for participation in Advisory Board from Roche and Takeda. J.B.S. has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Merck, Janssen, and Roche; honoraria for lectures from Bristol-Myers Squibb and Janssen; support for attending meetings and travel from AstraZeneca, Janssen, and Merck; payment for participation in Advisory Board from AstraZeneca, Bristol-Myers Squibb, Genmab, Janssen, Merck and Roche. E.M.U. has received research grants from AstraZeneca and Merck; speaker fees from Amgen; travel support related to participation in international scientific meeting from AstraZeneca, MSD, and Roche; and payment for participation in Advisory Board from AstraZeneca and Pfizer. The authors have no other conflicts of interest to declare.

Comment on

  • Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
    Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.

References

    1. Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med 2024;390:1265-76. 10.1056/NEJMoa2310532 - DOI - PubMed
    1. Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015;88:108-11. 10.1016/j.lungcan.2015.01.020 - DOI - PMC - PubMed
    1. Zou Z, Xing P, Hao X, et al. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study. BMC Med 2022;20:12. 10.1186/s12916-021-02207-x - DOI - PMC - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
    1. Besse B, Le Chevalier T. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? J Clin Oncol 2008;26:5014-7. 10.1200/JCO.2008.18.1081 - DOI - PubMed

LinkOut - more resources